RNS Number : 9597B
Genedrive PLC
04 February 2020

genedrive plc
("genedrive" or the "Company")

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that today David Budd, Chief Executive Officer, acquired 43,330 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 11.5p per share and Chris Yates, Non-Executive Director, acquired 25,000 Ordinary Shares at 11.56p per share.

Following these purchases, David Budd is interested in 188,710 Ordinary Shares, 0.5% of the issued share capital of the Company, and Chris Yates is interested in 41,304 Ordinary Shares, 0.1% of the issued share capital of the Company.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	***Details of the person discharging managerial responsibilities / person closely associated***	
a.	*Name*	*1. David Budd* *2. Chris Yates*
2.	***Reason for the notification***	
a.	*Position/status*	*1. Chief Executive Officer* *2. Non-Executive Director*
a.	*Initial notification /Amendment*	*Initial notification*
3.	***Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor***	
a.	*Name*	*genedrive plc*
b.	*LEI*	*213800ZYODIRZ87Y4K14*
4.	***Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted***	
a.	*Description of the Financial instrument, type of instrument*	*Ordinary shares of 1.5 pence each*

	Identification code	*GB00B1VKB244*
b.	*Nature of the transaction*	*Purchase*
c.	*Price(s) and volume(s)*	<table><tr><th>*Price(s)*</th><th>*Volume(s)*</th></tr><tr><td>*1. 11.50p* *2. 11.56p*</td><td>*1. 43,330* *2. 25,000*</td></tr></table>
d.	*Aggregated information* · *Aggregated volume* · *Price*	*N/A*
e.	*Date of the transaction*	*2020-02-04*
f.	*Place of the transaction*	*London Stock Exchange, AIM*

For further details please contact:

genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Jackson

Stanford Capital Partners Limited (Joint Broker) +44 (0)20 3815 8880
Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876 741 001

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEAKALEAFEEFA